L. T. Kulumbegova
Research Subjects
L. T. Kulumbegova has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- K. S. Ermolenko
Peoples’ Friendship University of Russia
3 shared publications - Alina V. Solovyeva
RUDN University
2 shared publications A.V. Markin
Group of Companies “Mother and Child”, Moscow
1 shared publication- D. P. Kamillova
Group of Companies “Mother and Child”, Moscow
1 shared publication - Darya S. Mamchich
RUDN University
1 shared publication - Ekaterina Yu. Aleynikova
Peoples’ Friendship University of Russia named after Patrice Lumumba
1 shared publication
Latest Publications
- Open Access
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 37-42
Use of estradiol valerate in women with thin endometrium in ART cycles
Introduction . Patients with infertility often require the help of assisted reproductive technologies to solve their problem. Two thirds of failures in ART cycles are associated with insufficient endometrial receptivity. Aim . To evaluate the effectiveness of using estradiol valerate 2 mg (Progynova®) in women with thin endometrium in ART cycles. Materials and methods . The study included patients with a thin endometrium ≤ 7.0 mm according to the ultrasound examination (US) of the pelvic organs on the 10–14th day of the menstrual cycle (peak of luteinizing hormone (LH) in the blood or on the day of progesterone administration in the hormone replacement therapy cycle). Patients with a thin endometrium (n = 74) were divided into two groups: the first group (n = 43) – patients with chronic endometritis established by histological examination and immunohistochemistry (IHC); group 2 (n=31) – patients with a thin endometrium without chronic endometritis. All patients received estradiol valerate according to one of the following regimens: 4 mg estradiol valerate in a natural cycle from the moment the dominant follicle reached a diameter of 13 mm or 4 mg estradiol valerate from day 3 of the menstrual cycle. Results. Administration of estradiol valerate statistically significantly increased the endometrial thickness in women with thin endometrium (p < 0.05). The increase in endometrial thickness in patients of group 1 averaged 1.9279 mm, in patients of group 2 – 2.09 mm. The average endometrial thickness before treatment with estradiol valerate was 6.315 (4.7; 7.0) mm, after treatment – 8.311 (5.6; 11.0). 70 of 74 (94.6%) patients had an endometrial thickness of > 7 mm. Pregnancy in an IVF or PE cycle occurred in 44 patients with thin endometrium (62.5%) after treatment with estradiol valerate. Conclusions. The use of estradiol valerate in IVF and ET cycles increases the thickness of the endometrium and increases the frequency of pregnancy and live birth in patients with a thin endometrium.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 37-42
Open AccessUse of estradiol valerate in women with thin endometrium in ART cycles
Introduction . Patients with infertility often require the help of assisted reproductive technologies to solve their problem. Two thirds of failures in ART cycles are associated with insufficient endometrial receptivity. Aim . To evaluate the effectiveness of using estradiol valerate 2 mg (Progynova®) in women with thin endometrium in ART cycles. Materials and methods . The study included patients with a thin endometrium ≤ 7.0 mm according to the ultrasound examination (US) of the pelvic organs on the 10–14th day of the menstrual cycle (peak of luteinizing hormone (LH) in the blood or on the day of progesterone administration in the hormone replacement therapy cycle). Patients with a thin endometrium (n = 74) were divided into two groups: the first group (n = 43) – patients with chronic endometritis established by histological examination and immunohistochemistry (IHC); group 2 (n=31) – patients with a thin endometrium without chronic endometritis. All patients received estradiol valerate according to one of the following regimens: 4 mg estradiol valerate in a natural cycle from the moment the dominant follicle reached a diameter of 13 mm or 4 mg estradiol valerate from day 3 of the menstrual cycle. Results. Administration of estradiol valerate statistically significantly increased the endometrial thickness in women with thin endometrium (p < 0.05). The increase in endometrial thickness in patients of group 1 averaged 1.9279 mm, in patients of group 2 – 2.09 mm. The average endometrial thickness before treatment with estradiol valerate was 6.315 (4.7; 7.0) mm, after treatment – 8.311 (5.6; 11.0). 70 of 74 (94.6%) patients had an endometrial thickness of > 7 mm. Pregnancy in an IVF or PE cycle occurred in 44 patients with thin endometrium (62.5%) after treatment with estradiol valerate. Conclusions. The use of estradiol valerate in IVF and ET cycles increases the thickness of the endometrium and increases the frequency of pregnancy and live birth in patients with a thin endometrium.
- Open Access
- 21 October 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 53-56
Replenishment of iron deficiency in women before the use of assisted reproductive technologies
Introduction. Anemia is a major health problem worldwide, increasing the risks of low birth weight, preterm birth, perinatal mortality, stillbirth, postpartum hemorrhage, and maternal mortality. Replenishing iron deficiency at the stage of preconceptional preparation reduces the incidence of IDA and can reduce the incidence of pregnancy complications and improve perinatal outcomes.Aim. To evaluate the effectiveness of ferrous sulfate 80 mg and its potential to replenish iron deficiency in women with infertility before using assisted reproductive technologies (ART).Materials and methods. A prospective clinical longitudinal study was conducted from May to September 2023 at LLC Health Clinic, Moscow. The study included women (n = 34) at the stage of pregnancy planning by IVF with a diagnosed iron deficiency. Iron deficiency was established in accordance with the following criteria: decrease in serum ferritin level less than 30 μg/l, serum iron level less than 15 μmol/l.Results. After 12 weeks of taking ferrous sulfate, the average hemoglobin level increased from 112.3 ± 6.5 (101–119) g/l to 118.5 ± 6.5 (110–133) g/l (W-Wilcoxon 9300 test, p = 0.003), mean serum iron level from 15.4 ± 4.0 (5.7–22.5) μmol/l to 34.8 ± 7.1 (20.1–46.7) μmol/l (Wilcoxon W test 602.0, p < 0.001), mean ferritin level from 8.2 ± 3.1 (4.5–17.0) μg/ml to 37.6 ± 6.7 (30.6–52.6) μg/ml (Wilcoxon W test 595.0, p < 0.001).Conclusions. Timely examination of patients for iron deficiency and iron deficiency anemia at the stage of preconceptional preparation makes it possible to prescribe an effective correction, thereby helping to reduce the risks of complications of pregnancy and childbirth.
- 21 October 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 53-56
Open AccessReplenishment of iron deficiency in women before the use of assisted reproductive technologies
Introduction. Anemia is a major health problem worldwide, increasing the risks of low birth weight, preterm birth, perinatal mortality, stillbirth, postpartum hemorrhage, and maternal mortality. Replenishing iron deficiency at the stage of preconceptional preparation reduces the incidence of IDA and can reduce the incidence of pregnancy complications and improve perinatal outcomes.Aim. To evaluate the effectiveness of ferrous sulfate 80 mg and its potential to replenish iron deficiency in women with infertility before using assisted reproductive technologies (ART).Materials and methods. A prospective clinical longitudinal study was conducted from May to September 2023 at LLC Health Clinic, Moscow. The study included women (n = 34) at the stage of pregnancy planning by IVF with a diagnosed iron deficiency. Iron deficiency was established in accordance with the following criteria: decrease in serum ferritin level less than 30 μg/l, serum iron level less than 15 μmol/l.Results. After 12 weeks of taking ferrous sulfate, the average hemoglobin level increased from 112.3 ± 6.5 (101–119) g/l to 118.5 ± 6.5 (110–133) g/l (W-Wilcoxon 9300 test, p = 0.003), mean serum iron level from 15.4 ± 4.0 (5.7–22.5) μmol/l to 34.8 ± 7.1 (20.1–46.7) μmol/l (Wilcoxon W test 602.0, p < 0.001), mean ferritin level from 8.2 ± 3.1 (4.5–17.0) μg/ml to 37.6 ± 6.7 (30.6–52.6) μg/ml (Wilcoxon W test 595.0, p < 0.001).Conclusions. Timely examination of patients for iron deficiency and iron deficiency anemia at the stage of preconceptional preparation makes it possible to prescribe an effective correction, thereby helping to reduce the risks of complications of pregnancy and childbirth.